Lipid nucleoside conjugates for the treatment of cancer

Current Pharmaceutical Design

Volumn 11, Issue 9, 2005, Pages 1079-1089

  Alexander, Richard L ^a   Kucera, Gregory L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Antimetabolites; Ara C; Fludarabine; Gemcitabine; Lipid drug conjugates; Synthetic phospholipids

Indexed keywords

CYTARABINE; DEOXYCYTIDINE KINASE; DRUG CARRIER; FLUDARABINE; GEMCITABINE; PRODRUG; URACIL ARABINOSIDE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; COLORECTAL CANCER; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TRANSPORT; ENZYME PHOSPHORYLATION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LIPIDS; NEOPLASMS; NUCLEOSIDES;

EID: 15544370683     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053507602     Document Type: Review

References (86)

1. Uchida K, Kreis W. Studies on drug resistance. I. Distribution of 1-beta-D-arabinofuranosylcytosine, cytidine and deoxycytidine in mice bearing ara-C-sensitive and-resistant P815 neoplasms. Biochemical Pharmacology 1969; 18: 1115-1128.
2. Ruiz van Haperen V, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, et al. Development and molecular characterization of a 2′, 2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Research 1994; 54: 4138-4143.
3. Steuart CD, Burke PJ. Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nature: New Biology 1971; 233: 109-110.
4. Tattersall MHN, Ganeshaguru K, Hoffbrand AV. Mechanisms of resistance of human acute leukemia cells to cytosine arabinoside. British Journal of Haematology 1974; 27: 39-46.
5. Kessel D, Hall TC, Rosenthal D. Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro Cancer Research 1969; 29: 459-463.
6. Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Experimental Hematology 1996; 24: 1340-1346.
7. Galmarini CM, Thomas X, Graham K, El Jafaari A, Cros E, Jordheim L, et al. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with Cytarabine. British Journal of Haematology 2003; 122: 53-60.
8. Mastrianni DM, Tung NM, Tenen DG. Acute myelogenous leukemia: current treatment and future directions. American Journal of Medicine 1992; 92: 286-295.
9. Early AP, Preisler HD, Slocum H. A pilot study of high dose 1-β-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Research 1982; 42: 1587-1594.
10. Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 1979; 44: 1189-1193.
11. Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P, Riggs S, et al. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. Journal of Clinical Oncology 1983; 1: 689-694.
12. Chabner BA, Myers CE. In: DeVita VT Jr, Hellman S, Rosenberg, SA. Ed, Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott 1989; 349-395.
13. Wiley JS, Jones SP, Sawyer WH, Paterson ARP. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. Journal of Clinical Investigation 1982; 69: 479-489.
14. Wiley JS, Jones SP, Sawyer WH. Cytosine arabinoside transport by human leukemia cells. European Journal of Cancer and Clinical Oncology 1983; 19: 1067-1074.
15. White JC, Rathmell JP, Capizzi RL. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. Journal of Clinical Investigation 1987; 79: 380-387.
16. Kessel D, Hall TC, Wodinsky I. Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science 1967; 156: 1240-1241.
17. Furth JJ, Cohen SS. Inhibition of mammalian DNA polymerase by the 5′triphosphate of 1-β-D-arabinofuranosylcytosine and 5′triphosphate of 1-β-D-arabinofuranosyladenine. Cancer Research 1968; 28: 2061-2067.
18. Momparler RL, Fischer GA. Mammalian deoxynucleoside kinases: I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. Journal of Biological Chemistry 1968; 243: 4298-4304.
19. Plagemann PGW, Marz R, Wohlhueter RM. Transport and metabolism of deoxycytidine and 1-β-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. Cancer Research 1978; 38: 978-989.
20. Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR. Cytosine arabinoside transport and metabolism in acute leukemia and T-cell lymphoblastic lymphoma. Journal of Clinical Investigation 1985; 75: 632-642.
21. Kufe DW, Munroe D, Herrick D, Egan E, Spriggs D. Effects of 1-β-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function. Molecular Pharmacology 1984; 26: 128-134.
22. Fram RJ, Kufe DW. DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin. Cancer Research 1982; 42: 4050-4053.
23. Ohno Y, Spriggs D, Matsukage A, Ohno T, Kufe D. Effects of 1-β-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase B. Cancer Research 1988; 48: 1494-1498.
24. Baker WJ, Royer GL Jr, Weiss RB. Cytarabine and neurologic toxicity. Journal of Clinical Oncology 1991; 9: 679-693.
25. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self- potentiation. Seminars in Oncology 1995; 22: 3-10.
26. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. Journal of Clinical Oncology 1992; 10: 406-413.
27. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′, 2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. Journal of the National Cancer Institute 1994; 86: 1530-1533.
28. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2, 2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Investigational New Drugs 1994; 12: 29-34.
29. Moore DF Jr, Pazdur R, Daugherty K, Tarassoff P, Abbruzzese JL. Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Investigational New Drugs 1992; 10: 323-325.
30. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. Journal of Clinical Oncology 1994; 12: 1821-1826.
31. Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 283-285.
32. Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 543-547.
33. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15: 3441-3445.
34. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, et al. Advanced breast cancer: a phase II trial with gemcitabine. Journal of Clinical Oncology 1995; 13: 2731-2736.
35. De Mulder PH, Weissbach L, Jakse G, Osieka R, Blatter J. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemotherapy & Pharmacology 1996; 37: 491-495.
36. Heinemann V, Schulz L, Issels RD, Plunkett W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Seminars in Oncology 1995; 22: 11-18.
37. Bouffard DY, Laliberte J, Momparler RL. Kinetic studies on 2′, 2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochemical Pharmacology 1993; 45: 1857-1861.
38. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Seminars in Oncology 1995; 22: 19-25.
39. Bouffard DY, Momparler RL. Comparison of the induction of apoptosis in human leukemic cell lines by 2′, 2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leukemia Research 1995; 19: 849-856.
40. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anti-Cancer Drugs 1995; 6 Suppl 6: 7-13.
41. Plunkett W. In: Aapro MS Ed, Innovative Antimetabolites in Solid Tumours. New York, Springer-Verlag 1994; 11-19.
42. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′, 2′-difluorodeoxycytidine. Molecular Pharmacology 1990; 38: 567-572.
43. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Seminars in Oncology 1990; 17 Suppl 8: 3-17.
44. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemotherapy & Pharmacology 1995; 36: 181-188.
45. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2- fluoroadenine. A mechanism for cytotoxicity. Journal of Biological Chemistry 1990; 265: 16617-16625.
46. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19-25.
47. Hutton JJ, Von Hoff DD, Kuhn J, Phillips J, Hersh M, Clark G. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Research 1984; 44: 4183-4186.
48. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New England Journal of Medicine 1992; 327: 1056-1061.
49. Mansson E, Flordal E, Liliemark J, Spasokoukotskaja T, Elford H, Lagercrantz S, et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochemical Pharmacology 2003; 65: 237-247.
50. Skalski V, Brown KR, Choi BY, Lin ZY, Chen S. A 3′-5′ exonuclease in human leukemia cells: implications for resistance to 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate. Journal of Biological Chemistry 2000; 275: 25814-25819.
51. Alberti A. Chemical aspects of selective toxicity. Nature: New Biology 1958; 182: 421-423.
52. Testa B. In: Wolff ME Ed, Burger's Medicinal Chemistry and Drug Discovery. New York, Wiley-Interscience 1995; 129-180.
53. Testa B, Caldwell J. Prodrugs revisited: the "ad hoc" approach as a complement to ligand design. Medicinal Research Reviews 1996; 16: 233-241.
54. Lambert DM. Rationale and applications of lipids as prodrug carriers. European Journal of Pharmaceutical Science 2000; 11: S15-S27.
55. Liu DZ, Morris-Natschke SL, Kucera LS, Ishaq KS, Thakker DR. Structure-activity relationships for enhancement of paracellular permeability by 2-alkoxy-3-alkylamidopropylphosphocholines across Caco-2 cell monolayers. Journal of Pharmaceutical Science 1999; 88: 1169-1174.
56. Wechter WJ, Johnson MA, Hall CM, Warner DT, Berger AE, Wenzel AH, et al. ara-Cytidine acylates. Use of drug design predictors in structure-activity relationship correlation. Journal of Medicinal Chemistry 1975; 18: 339-344.
57. Warner DT, Neil GL, Taylor AJ, Wechter WJ. Nucleic acids. 13. 3′-O- and 2′-O-esters of 1- -D-arabinofuranosylcytosine as antileukemic and immunosuppressive agents. Journal of Medicinal Chemistry 1972; 15: 790-792.
58. Hamamura EK, Prystasz M, Verheyden JPH, Moffatt JG. Reactions of 2-acyloxyisobutyryl halides with nucleosides. Synthesis and biological evaluation of some 3′-acyl and 3′, 5′-diacyl derivatives of 1-β-D-arabinofuranosylcytosine. Journal of Medicinal Chemistry 1976; 19: 667-674.
59. Raetz CRH, Chu MY, Srivastava SP, Turcotte JG. A phospholipid derivative of cytosine arabinoside and its conversion to phosphatidylinositol by animal tissue. Science 1977; 196: 303-304.
60. MacCoss M, Ryu EK, Matsushita T. The synthesis, characterization, and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine-5′-diphosphate-L-1, 2-dipalmitin. Biochemical and Biophysical Research Communications 1978; 85: 714-723.
61. Matsushita T, Ryu EK, Hong CI, MacCoss M. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability. Cancer Research 1981; 41: 2707-2713.
62. Ryu EK, Ross RJ, Matsushita T, MacCoss M, Hong CI, West CR. Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5′-monophosphate-L-1, 2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1, 2-diacylglycerols. Journal of Medicinal Chemistry 1982; 25: 1322-1329.
63. Hong CI, An SH, Buchheit DJ, Nechaev A, Kirisits AJ, West CR, et al. 1-beta-D-arabinofuranosylcytosine-phospholipid conjugates as prodrugs of Ara-C. Cancer Drug Delivery 1984; 1: 181-190.
64. Hong CI, An SH, Buchheit DJ, Nechaev A, Kirisits AJ, West CR, et al. Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. Journal of Medicinal Chemistry 1986; 29: 2038-2044.
65. Hong CI, Kirisits AJ, Buchheit DJ, Nechaev A, West CR. 1-beta-D-arabinofuranosylcytosine conjugates of thioether phospholipids as a new class of potential antitumor drugs. Cancer Drug Delivery 1986; 3: 101-113.
66. Hong CI, Kirisits AJ, Nechaev A, Buchheit DJ, West CR. Nucleoside conjugates. 11. Synthesis and antitumor activity of 1-β-D-arabinofuranosylcytosine and cytidine conjugates of thioether lipids. Journal of Medicinal Chemistry 1990; 33: 1380-1386.
67. Hong CI, An SH, Nechaev A, Kirisits AJ, Vig R, West CR. Synthesis and antitumor activity of 1-beta-D- arabinofuranosylcytosine conjugates of optical isomers of ether and thioether lipids. Lipids 1993; 28: 1021-1026.
68. Morris-Natschke S, Surles JR, Daniel LW, Berens ME, Modest EJ, Piantadosi C. Synthesis of sulfur analogues of alkyl lysophospholipid and neoplastic cell growth inhibitory properties. Journal of Medicinal Chemistry 1986; 29: 2114-2117.
69. Runge MH, Andreesen R, Pfleiderer A, Munder PG. Destruction of human solid tumors by alkyl lysophospholipids. Journal of the National Cancer Institute 1980; 64: 1301-1306.
70. Surles JR, Morris-Natschke S, Marx MH, Piantadosi C. Multigram synthesis of 1-alkylamido phospholipids. Lipids 1993; 28: 55-57.
71. Hong CI, Bernacki RJ, Hui SW, Rustum Y, West CR. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid. Cancer Research 1990; 50: 4401-4406.
72. Hong CI, Nechaev A, Kirisits AJ, Vig R, West CR. Nucleoside conjugates. 13. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of thioether lipids with improved water solubility. Journal of Medicinal Chemistry 1993; 36: 1785-1790.
73. Brachwitz H, Bergmann J, Fichtner I, Thomas Y, Vollgraf C, Langen P, et al. 1-beta-D-Arabinofuranosylcytosine-5′-alkylphosphonophosphates and diphosphates: new orally active derivatives of ara-C. Journal of Lipid Research 1998; 39: 162-172.
74. Brachwitz H, Bergmann J, Thomas Y, Wollny T, Langen P. Synthesis and antiproliferative potency of 9-beta-D-arabinofuranosyl-2-fluoroadenine phospholipid adducts. Bioorganic and Medicinal Chemistry 1999; 7: 1195-1200.
75. Alexander RL, Morris-Natschke SL, Ishaq KS, Fleming RA, Kucera GL. Synthesis and Cytotoxic Activity of Two Novel 1-Dodecylthio-2decyloxy-propyl-3-phosphatidic Acid Conjugates with Gemcitabine and Cytosine Arabinoside. Journal of Medicinal Chemistry 2003; 46: 4205-4208.
76. Kurz M, Scriba GK. Drug-phospholipid conjugates as potential prodrugs: synthesis, characterization, and degradation by pancreatic phospholipase A(2). Chemistry and Physics of Lipids 2000; 107: 143-157.
77. Piantadosi C, Marasco CJ Jr, Morris-Natschke SL, Meyer KL, Gumus F, Surles JR, et al. Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity. Journal of Medicinal Chemistry 1991; 34: 1408-1414.
78. Herrmann DBJ, Menschik V, Opitz HG. Intracellular metabolism of the new anti-AIDS compound Fozivudine in isolated human peripheral blood leukocytes. Naunyn-Schmiedebergs Archives of Pharmacology 1997; 356: Sept. 14-17; Abstract 175: pR44.
79. Kucera GL, Goff CL, Iyer N, Morris-Natschke S, Ishaq KS, Wyrick S, et al. Cellular metabolism in lymphocytes of a novel thioether-phospholipid-AZT conjugate with anti-HIV-1 activity. Antiviral Research 2001; 50: 129-137.
80. Persons DA, Wilkison WO, Bell RM, Fin OJ. Altered growth regulation and enhanced tumorigenicity of NIH 3T3 fibroblasts transfected with protein kinase C-1 cDNA. Cell 1988; 52: 447-458.
81. Housey GM, Johnson MD, Hsaio WLM, O'Brian CA, Murphy JP, Kirshmeier P, et al. Overproduction of protein kinase C causes disordered growth control in rat fibroblasts. Cell 1988; 52: 343-354.
82. Mavromoustakos T, Calogeropoulou T, Koufaki M, Kolocouris A, Daliani I, Demetzos C, et al. Ether phospholipid-AZT conjugates possessing anti-HIV and antitumor cell activity. Synthesis, conformational analysis, and study of their thermal effects on membrane bilayers. Journal of Medicinal Chemistry 2001; 44: 1702-1709.
83. Lin, Tai-Shun, Prusoff WH. In: Townsend LB, Tipson RS Ed, Nucleic Acid Chemistry. New York, John Wiley & Sons 1978; 261-272.
84. Gero AM, Dunn CG, Brown DM, Pulenthiran K, Gorovits EL, Bakos T, et al. New malaria chemotherapy developed by utilization of a unique parasite transport system. Curr Pharm Design 2003; 9(11): 867-77.
85. Morris-Natschke SL, Ishaq KS, Kucera LS. Phospholipid analogs against HIV-1 infection and disease. Curr Pharm Design 2003; 9(18): 1441-51.
86. Venkatachalam TK, Goodman PA, Qazi S, D'Cruz O, Uckun FM. Rational drug design of multifunctional phosphoramidate substituted nucleoside analogs. Curr Pharm Design 2004; 10(15): 1713-26.